Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Schedule of Segment Information (Details)

v3.21.1
Segment Information - Schedule of Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Apr. 30, 2021
Apr. 30, 2020
Apr. 30, 2021
Apr. 30, 2020
Oct. 31, 2020
Net Income/(Loss) $ (2,436,889) $ (2,657,990) $ (4,669,266) $ (5,274,565)  
Total operating costs and expenses 2,437,282 2,670,137 5,182,913 5,300,006  
Less non-cash share-based compensation (1,051,272) (1,110,086) (2,037,371) (2,131,420)  
Operating costs and expenses excluding non-cash share-based compensation 1,386,010 1,560,051 3,145,542 3,168,586  
Total assets 38,497,522   38,497,522   $ 9,452,964
CAR-T Therapeutics [Member]          
Net Income/(Loss) (1,445,758) (495,030) (2,406,494) (1,125,363)  
Operating costs and expenses excluding non-cash share-based compensation 934,714 223,822 1,492,394 570,163  
Total assets 25,906,018   25,906,018   2,988,124
Cancer Vaccines [Member]          
Net Income/(Loss) (662,367) (170,271) (1,568,703) (365,867)  
Operating costs and expenses excluding non-cash share-based compensation 298,537 67,059 836,525 165,329  
Total assets 8,265,734   8,265,734   946,923
Anti-Viral Therapeutics [Member]          
Net Income/(Loss) (309,755) (309,504) (790,561) (309,504)  
Operating costs and expenses excluding non-cash share-based compensation 138,175 221,018 408,431 221,018  
Total assets 3,825,876   3,825,876   2,464,361
Cancer Diagnostics [Member]          
Net Income/(Loss) (13,409) (1,679,027) (22,371) (3,469,673)  
Operating costs and expenses excluding non-cash share-based compensation 10,291 1,044,889 16,723 2,208,813  
Total assets 332,450   332,450   2,869,529
Patent Licensing [Member]          
Net Income/(Loss) (5,600) (4,158) 118,863 (4,158)  
Operating costs and expenses excluding non-cash share-based compensation 4,293 $ 3,263 391,469 $ 3,263  
Total assets $ 167,444   $ 167,444   $ 184,027